Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-BFM 2004 liposomal daunorubicin optimization in pediatric AML
2006-004710-41Phase 3Completed
- Sponsor
- St. Anna Children's Cancer Research Institute
- Start
- Oct 2006
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3 trial of liposomal daunorubicin and cladribine in acute myeloid leukemia (AML), sponsored by St. Anna Children's Cancer Research Institute. Primary endpoints: overall survival and event-free survival. Started Oct 2006; status: completed.
02
Drugs
liposomal daunorubicincladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-004710-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004710-41.